The experienced CEOs on this panel have authored some of the greatest stories in Medtech. In this discussion, they delve into their approaches to managing start-ups to multi-million – or billion – dollar acquisitions or IPOs. How do they accurately assess a struggling company and direct a team to turn weakness into strength?
Thom Gunderson, Former Medical Device Analyst – Piper Jaffray
Michael Ackermann, Former CEO – Oculeve (Now with Allergan)
Andrew Cleeland, Former CEO – Twelve (Now with Medtronic)
Michael DeMane, Chairman & CEO – Nevro
Keith Grossman, Former CEO, President & Director – Thoratec
For over 20 years Thom Gunderson was a managing director and senior research analyst at Piper Jaffray, following medical technology companies.
Michael is currently Vice President, Neurostimulation for Allergan, plc, and most recently CEO of Oculeve, Inc., which was acquired by Allergan in August 2015.
Andrew Cleeland is an executive with 27 years in medtech in both private and public sector roles. Andrew is currently Vice President/General Manager of Medtronic’s Transcatheter Mitral Valve Venture following its recent acquisition of Twelve Inc., where he was the president and CEO.
Michael DeMane joined Nevro in 2011 and is the Chairman and CEO of the Company. Mr. DeMane is a veteran medical device executive, having held leadership roles in the US, Europe and Australia over the past 30 years.
D. Keith Grossman
Named CEO and President of Thoratec Corp. (THOR) for the second time in 2014, Mr. Grossman led the company’s return to growth, and to its $3.4 billion acquisition by St. Jude Medical in 2015. Prior to Thoratec, he served as CEO and President of Conceptus, Inc.